Plain-English translation of NCT07263022 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This research study is testing whether two medications— and d-serine—can help improve thinking, memory, and other cognitive abilities in people who have recently experienced psychosis (a mental health condition involving loss of touch with reality). Researchers will use brain imaging scans to see how these medications affect brain activity and cognitive function, comparing them to placebo.
People with early psychosis often experience difficulties with thinking and memory that can affect their daily lives and recovery. This study exists to find safe, effective ways to help improve these cognitive problems during the early stages of illness, when treatment may have the most benefit.
You likely qualify if…
You likely don't qualify if…
You will attend 10 appointments over several weeks. The first visit is an intake appointment (about 2 hours) where you'll answer questions about your medical and mental health history and provide a small blood sample. You'll then have 6 brain imaging visits at a university research center, each lasting about 7–7.5 hours, where you'll take a single dose of one of the study medications (or placebo) before undergoing an MRI scan to see how it affects your brain. Between and after these visits, you'll have brief check-in appointments and phone calls to monitor how you're doing.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
United States